• The Canadian Task Force on Preventive Health Care concludes that there is fair evidence to recommend screening postmenopausal women to prevent fragility fractures (no or low trauma) (grade B recommendation). Although there is no direct evidence that screening reduces fractures, there is good evidence that screening is effective in identifying postmenopausal women with low bone mineral density (BMD) and that treating osteoporosis can reduce the risk of fractures (grade A recommendation).
Overall recommendations
• The Canadian Task Force on Preventive Health Care concludes that there is fair evidence to recommend screening postmenopausal women to prevent fragility fractures (no or low trauma) (grade B recommendation). Although there is no direct evidence that screening reduces fractures, there is good evidence that screening is effective in identifying postmenopausal women with low bone mineral density (BMD) and that treating osteoporosis can reduce the risk of fractures (grade A recommendation).
• For women who screen positive for osteoporosis, there is good to fair evidence that therapy with alendronate, risedronate or raloxifene prevents osteoporotic fractures (grade A to B recommendation).
• For women with severe osteoporosis (osteoporosis plus at least 1 fragility fracture), there is good to fair evidence to recommend the use of alendronate, risedronate, parathyroid hormone (limited duration), raloxifene, etidronate and oral pamidronate therapy (grade A to B recommendation). If none of these drugs is tolerated, hormone replacement therapy (HRT) or calcitonin can be considered. (In a recent position statement, the task force recommended against combined estrogen-progestin therapy as well as unopposed estrogen therapy for the primary prevention of chronic diseases [grade D recommendation].
1 ) • For women without documented osteoporosis, there is fair evidence that calcium and vitamin D supplementation alone prevents osteoporotic fractures (grade B recommendation). There is fair evidence that combined estrogen-progestin therapy decreases the incidence of total, hip and nonvertebral fractures; however, for most women the risks may outweigh the benefits (grade D recommendation). (As noted above, the task force recently recommended against HRT for the primary prevention of chronic diseases [grade D recommendation].
)

Manoeuvres
Screening
• There is fair evidence to recommend using history of previous fracture for the prediction of osteoporotic fractures (grade B recommendation).
• There is good evidence to recommend using either the SCORE questionnaire (Appendix 1) or the ORAI instrument (Appendix 2) to predict low BMD (grade A recommendation) and fair evidence to recommend screening using BMD to predict fractures (grade B recommendation).
• There is fair evidence to recommend BMD screening using DEXA (dual energy x-ray absorptiometry) to prevent fractures in postmenopausal women who (a) are 65 years or older, (b) weigh less than 60 kg, (c) have a history of previous fracture, (d) have an ORAI score of 9 or greater, or (e) have a score of 6 or greater on the SCORE questionnaire (grade B recommendation).
• There is insufficient evidence to recommend using bone turnover markers to predict fractures (grade I recommendation). The recommendations in this statement apply to most postmenopausal women in the general population, including those who have late menarche, early menopause, low calcium intake, low physical activity, high alcohol or caffeine intake, low body weight, a family history of osteoporosis or osteoporotic fractures or a history of hyperthyroidism or who are smokers. However, they do not apply to women who have specific conditions that predispose them to significant increased risk of fractures, including women taking steroids, those with hyperparathyroidism and those in nursing homes. These recommendations are meant to guide physicians in their discussions with their postmenopausal patients, as each individual woman may have unique risks and preferences. The recommended age for initiation of screening is based on the prevalence of osteoporosis and fractures among postmenopausal women in the different age groups (Table 1) . Our recommendations are the most conservative of recent Canadian guidelines (see "Recommendations of others") and are based on fracture data rather than on bone mineral density (BMD) data, since we do not know how short-term BMD differences translate into long-term fracture outcomes, especially among women without osteoporosis. A unique feature of our guidelines is that we do not recommend using drug therapy for the primary prevention of osteoporosis. More than 45% of postmenopausal women have osteopenia. 2 The fracture risk for most of these women is low. Because risk of fracture increases with age, it may be reasonable to consider prescribing drug therapy for women who are 65 or older and who have a T score below -2.0.
Primary prevention
Background
Burden of illness
Osteoporosis affects 1 in 6 Canadian women over the age of 50. 2 The Canadian Multicentre Osteoporosis Study (CaMOS), a prospective population-based mixed cohort study involving 9423 Canadians over 25, showed the prevalence of osteoporosis among Canadian women 50 years and older to be 12.1% in the lumbar spine and 7.9% in the femoral neck, for a combined prevalence of 15.8%. The prevalence of osteopenia at the femoral neck among these women was 45.9%. Osteopenia and osteoporosis affect more women than men, usually in their postmenopausal years because of the lack of estrogen. The loss of bone mass occurs when there is more bone-
• There is fair evidence that HRT prevents total fractures (ARR 2.1%, NNT 48); however, for most postmenopausal women without menopausal symptoms, the risks may outweigh the benefits (grade D recommendation).
1
• There is insufficient evidence to recommend for or against the use of other pharmacological therapies for the prevention of fractures in postmenopausal women without osteoporosis, especially those less than 65 years old who have T scores greater than -2.0 (grade I recommendation). Treatment • There is insufficient evidence that combination therapy regimens are more effective than single therapy regimens in preventing fractures (grade I recommendation) and thus are not recommended as first-line therapy.
• It is unclear how long osteoporotic women should take these therapies. Most trials have fracture data for 5 years or less, with safety data for up to 10 years. For postmenopausal women with osteoporosis but without prevalent fractures:
• There is good evidence that alendronate (grade A recommendation) and fair evidence that risedronate and raloxifene (grade B recommendation) prevent vertebral fractures. resorptive than bone-formation activity, as in the case of postmenopausal osteoporosis. 2 Osteoporotic fracture is the main consequence of osteoporosis. About 40% of 50 year-old white women in Canada will have a clinical osteoporotic fracture during their remaining lifetime: 15.6% will experience a vertebral fracture, 16 .0% a wrist fracture and 17.5% a hip fracture. 3 Only onethird of vertebral fractures present as clinical fractures, the remainder going undiagnosed. Thus, vertebral fractures are the most common osteoporotic fracture in postmenopausal women; 46.8% of 50-year-old white women will experience 1 or more vertebral fractures in their remaining lifetime. In 1993, over 60 000 women were estimated to have osteoporosis-related fractures in Canada. 6 These fractures were responsible for more than 29 000 hospital admissions and 643 000 hospital days. An additional 47 000 fractures required outpatient care, and nearly 23 000 women were in either longterm or chronic care facilities because of osteoporotic fractures. In 1992, 1390 people in Canada died of complications associated with osteoporotic fractures. These numbers are expected to increase exponentially as our elderly population grows. By 2041, the costs of hip fractures alone are expected to rise to $2.4 billion. 
Definitions
Osteoporosis is a systemic disease characterized by low bone mass and microarchitectural deterioration of bone tissue, resulting in bone fragility and an increased risk of fractures. 8 Diagnostic criteria for osteoporosis in postmenopausal women are based on BMD, although the recent National Institutes of Health definition for osteoporosis incorporates bone quality. 9 A BMD value greater or equal to 2.5 standard deviations (SD) below the mean for young adults is defined as osteoporosis, and a BMD value between 1 and 2.5 SD below the mean for young adults is defined as osteopenia. The number of SD above (+) or below (-) the mean for young adults is called the T score, and the number of SD above or below the mean for one's own age group is called the Z score. A woman who has a T score of -2.0 and a Z score of -1.0 has a bone density that is 2 SD below the mean for young adults and 1 SD below the mean for her age-matched control group. Thus, postmenopausal women with T scores of -2.5 or below are classified as having osteoporosis. Although these diagnostic criteria have been widely adopted in clinical practice and research, their significance is not entirely clear because a "fracture threshold" does not exist.
The term severe osteoporosis is used to describe the condition of anyone who has osteoporosis and has had an osteoporotic fracture (often a fragility, low-trauma or atraumatic fracture that occurs when a minor loading force exceeds the strength of the bone). The occurence of a fracture depends not only on the biomechanical (e.g., BMD) and geometric properties of the bone but also on the magnitude, rate and direction of the loading force and the soft-tissue padding at the impact site. By convention, we define any spontaneous fractures, any fractures resulting from activities of daily living and any fractures resulting from a fall from standing height as fragility fractures. 
Potential harms
• Costs and radiation exposure from unnecessary BMD tests • Side effects of specific treatments
Recommendations of others
The US Preventive Services Task Force recommends that women 65 and older be screened routinely for osteoporosis and that those at increased risk of osteoporotic fractures, especially those with low body weight (wt < 70 kg) begin screening at age 60 (grade B recommendation). 30 The recent Osteoporosis Society of Canada guidelines recommend screening with DEXA (dual energy x-ray absorptiometry) for postmenopausal women who have 1 major and 2 minor clinical risk factors (Box 1) or for those 65 and over. 31 They also recommend using bisphosphonates and raloxifene as first-line therapy for the prevention and treatment of osteoporosis, HRT as first-line therapy for the prevention of osteoporosis and as second-line therapy for the treatment of osteoporosis (although risks may outweigh benefits) and nasal calcitonin therapy as second-line therapy for the treatment of osteoporosis. In addition, they recommend using parathyroid hormone as first-line therapy for the treatment of severe osteoporosis.
The Society of Obstetricians and Gynaecologists of Canada (SOGC) guidelines, published before the release of the Women's Health Initiative (WHI) results, recommend using HRT, raloxifene and the bisphosphonates (all grade 1 recom- [10] [11] [12] There is also good evidence that the SCORE questionnaire 13 (Appendix 1) and the ORAI instrument 14 (Appendix 2), which are used to screen for risk by determining combinations of identified risk factors, predict low BMD and that screening using BMD predicts fractures (RR 1.5-2.3). 15 It is unclear whether screening using bone turnover markers predicts fractures.
• The ability of BMD to predict fractures is greater than that of blood pressure to predict stroke and of cholesterol to predict cardiovascular disease. DEXA is the current "gold standard" for assessing BMD; it is easy to administer, the dose of radiation is low (equivalent to one-fifth to half of the dose used for a chest x-ray depending on the machine used and number of sites measured). Quantitative CT is not recommended for routine clinical use because it is time-consuming, requires much larger doses of radiation and is more costly than DEXA. Although quantitative ultrasonography is cheap and does not involve radiation, it has poorer precision than DEXA (i.e., it is not a good tool for following changes in BMD over time 
